Third Harmonic Bio Inc. (THRD) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Third Harmonic Bio Inc. stock (THRD) is currently trading at $5.38. Analyst consensus price target for THRD is $3.00. WallStSmart rates THRD as Sell.
- THRD PE ratio analysis and historical PE chart
- THRD PS ratio (Price-to-Sales) history and trend
- THRD intrinsic value — DCF, Graham Number, EPV models
- THRD stock price prediction 2025 2026 2027 2028 2029 2030
- THRD fair value vs current price
- THRD insider transactions and insider buying
- Is THRD undervalued or overvalued?
- Third Harmonic Bio Inc. financial analysis — revenue, earnings, cash flow
- THRD Piotroski F-Score and Altman Z-Score
- THRD analyst price target and Smart Rating
Third Harmonic Bio Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Third Harmonic Bio Inc. (THRD) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Third Harmonic Bio Inc. (THRD) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
80.12% of shares held by major funds and institutions
Third Harmonic Bio Inc. (THRD) Areas to Watch (2)
Company is destroying shareholder value
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Third Harmonic Bio Inc. (THRD) Detailed Analysis Report
Overall Assessment
This company scores 22/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 2 register as strengths (avg 10.0/10) while 2 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own.. Valuation metrics including Price/Book (0.89) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Market Cap. Profitability pressure is visible in Return on Equity at -19.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -19.90% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
THRD Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
WallStSmart Analysis Synopsis
Data-driven financial summary for Third Harmonic Bio Inc. (THRD) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Third Harmonic Bio Inc. operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.01 indicates a conservative balance sheet with 272M in cash.
Free cash flow is -13M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.13, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Third Harmonic Bio Inc..
Bottom Line
Third Harmonic Bio Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Third Harmonic Bio Inc.(THRD)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Third Harmonic Bio Inc. is a pioneering biotechnology firm focused on creating groundbreaking therapies for severe immunology and inflammation-related disorders. Leveraging a proprietary genetic engineering platform, the company is advancing an innovative pipeline of drug candidates designed to meet critical unmet medical needs in this therapeutic area. With a strong dedication to scientific rigor and enhancing patient outcomes, Third Harmonic Bio is well-positioned to make a significant impact on the biopharmaceutical sector and improve the quality of care for patients confronting substantial health challenges.